Research Center for Advanced Technologies in Cardiovascular Medicine, Tehran Heart Center, Tehran University of Medical Sciences, Tehran 1411713138, Iran.
University Hospital Centre Zagreb, School of Medicine University of Zagreb, Department of Internal Medicine, 1000 Zagreb, Croatia.
Biomolecules. 2019 Aug 26;9(9):416. doi: 10.3390/biom9090416.
Chronic inflammation is one of the main determinants of atherogenesis. The traditional medications for treatment of atherosclerosis are not very efficient in targeting atherosclerotic inflammation. Most of these drugs are non-selective, anti-inflammatory and immunosuppressive agents that have adverse effects and very limited anti-atherosclerotic effects, which limits their systemic administration. New approaches using nanoparticles have been investigated to specifically deliver therapeutic agents directly on atherosclerotic lesions. The use of drug delivery systems, such as polymeric nanoparticles, liposomes, and carbon nanotubes are attractive strategies, but some limitations exist. For instance, nanoparticles may alter the drug kinetics, based on the pathophysiological mechanisms of the diseases. In this review, we will update pathophysiological evidence for the use of nanoparticles to reduce inflammation and potentially prevent atherogenesis in different experimental models.
慢性炎症是动脉粥样硬化形成的主要决定因素之一。传统的治疗动脉粥样硬化的药物在靶向动脉粥样硬化炎症方面效果不是很好。这些药物大多数是非选择性的抗炎和免疫抑制剂，具有不良反应，并且对动脉粥样硬化的作用非常有限，这限制了它们的全身给药。已经研究了使用纳米粒子的新方法来专门将治疗剂直接递送到动脉粥样硬化病变部位。使用药物递送系统，如聚合物纳米粒子、脂质体和碳纳米管，是一种有吸引力的策略，但也存在一些局限性。例如，纳米粒子可能会根据疾病的病理生理机制改变药物动力学。在这篇综述中，我们将更新使用纳米粒子减轻炎症和潜在预防不同实验模型中动脉粥样硬化形成的病理生理学证据。
